BACKGROUND: Recurrent Clostridium difficile infection (rCDI) affects 10% to 25% of patients with initial CDI (iCDI). Initiation of new therapies that reduce recurrences rests on identifying patients at high risk for rCDI at iCDI onset. OBJECTIVE: To develop a predictive model for rCDI based on factors present at iCDI onset. DESIGN: Retrospective cohort study. SETTING: Large urban academic medical center. PATIENTS: All adult patients with an inpatient iCDI from January 1, 2003 to December 31, 2009. INTERVENTION: None. MEASUREMENTS: Positive toxin assay for C difficile with no C difficile infection in the previous 60 days constituted iCDI. Repeat positive toxin within 42 days of stopping iCDI treatment defined rCDI. Three demographic, 13 chronic, and 12 acute disease characteristics, and 7 processes of care prior to or at the onset of iCDI, were assessed for association with rCDI. A logistic regression model to identify predictors for rCDI was developed and cross-validated. RESULTS: Among the 4196 patients enrolled, 425 (10.1%) developed rCDI. Six factors (case status as community-onset healthcare-associated, ≥2 hospitalizations in the prior 60 days, new gastric acid suppression, fluoroquinolone and high-risk antibiotic use at the onset of iCDI, age) predicted rCDI in multivariate analyses, whereas intensive care unit stay appeared protective. The model achieved moderate discrimination (C statistic 0.643) and calibration (Brier score 0.089). Its negative predictive value was 90% or higher across a wide range of risk. CONCLUSIONS: Among patients hospitalized with rCDI, multiple factors present at the onset of iCDI increased the risk for rCDI. Recognizing patients at high-risk for rCDI can help clinicians tailor early treatment and prevention.
BACKGROUND: Recurrent Clostridium difficileinfection (rCDI) affects 10% to 25% of patients with initial CDI (iCDI). Initiation of new therapies that reduce recurrences rests on identifying patients at high risk for rCDI at iCDI onset. OBJECTIVE: To develop a predictive model for rCDI based on factors present at iCDI onset. DESIGN: Retrospective cohort study. SETTING: Large urban academic medical center. PATIENTS: All adult patients with an inpatient iCDI from January 1, 2003 to December 31, 2009. INTERVENTION: None. MEASUREMENTS: Positive toxin assay for C difficile with no C difficile infection in the previous 60 days constituted iCDI. Repeat positive toxin within 42 days of stopping iCDI treatment defined rCDI. Three demographic, 13 chronic, and 12 acute disease characteristics, and 7 processes of care prior to or at the onset of iCDI, were assessed for association with rCDI. A logistic regression model to identify predictors for rCDI was developed and cross-validated. RESULTS: Among the 4196 patients enrolled, 425 (10.1%) developed rCDI. Six factors (case status as community-onset healthcare-associated, ≥2 hospitalizations in the prior 60 days, new gastric acid suppression, fluoroquinolone and high-risk antibiotic use at the onset of iCDI, age) predicted rCDI in multivariate analyses, whereas intensive care unit stay appeared protective. The model achieved moderate discrimination (C statistic 0.643) and calibration (Brier score 0.089). Its negative predictive value was 90% or higher across a wide range of risk. CONCLUSIONS: Among patients hospitalized with rCDI, multiple factors present at the onset of iCDI increased the risk for rCDI. Recognizing patients at high-risk for rCDI can help clinicians tailor early treatment and prevention.
Authors: Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly Journal: Anaerobe Date: 2015-04-27 Impact factor: 3.331
Authors: Julia Origüen; María Ángeles Orellana; Mario Fernández-Ruiz; Laura Corbella; Rafael San Juan; María Ruiz-Ruigómez; Francisco López-Medrano; Manuel Lizasoain; Tamara Ruiz-Merlo; Guillermo Maestro-de la Calle; Patricia Parra; Jennifer Villa; Rafael Delgado; José María Aguado Journal: J Clin Microbiol Date: 2019-01-30 Impact factor: 5.948
Authors: Gabriel J Escobar; Jennifer M Baker; Patricia Kipnis; John D Greene; T Christopher Mast; Swati B Gupta; Nicole Cossrow; Vinay Mehta; Vincent Liu; Erik R Dubberke Journal: Infect Control Hosp Epidemiol Date: 2017-08-24 Impact factor: 3.254
Authors: Kelly R Reveles; Eric M Mortensen; Jim M Koeller; Kenneth A Lawson; Mary Jo V Pugh; Sarah A Rumbellow; Jacqueline R Argamany; Christopher R Frei Journal: Pharmacotherapy Date: 2018-02-22 Impact factor: 4.705
Authors: James Baggs; Kimberly Yousey-Hindes; Elizabeth Dodds Ashley; James Meek; Ghinwa Dumyati; Jessica Cohen; Matthew E Wise; L Clifford McDonald; Fernanda C Lessa Journal: Vaccine Date: 2015-10-09 Impact factor: 3.641
Authors: Caroline C Jozefczyk; W Justin Moore; Paul R Yarnold; Nathaniel J Rhodes; Karolina Harkabuz; Robert Maxwell; Sarah H Sutton; Christina Silkaitis; Chao Qi; Richard G Wunderink; Teresa R Zembower Journal: Antimicrob Agents Chemother Date: 2021-06-17 Impact factor: 5.191
Authors: Marya D Zilberberg; Andrew F Shorr; William M Jesdale; Jennifer Tjia; Kate Lapane Journal: Medicine (Baltimore) Date: 2017-03 Impact factor: 1.889
Authors: Salvador López-Cárdenas; Eva Torres-Martos; Juan Mora-Delgado; Juan Manuel Sánchez-Calvo; Marta Santos-Peña; Ángel Zapata López; María Dolores López-Prieto; Salvador Pérez-Cortés; Juan Carlos Alados Journal: Gut Microbes Date: 2021-03-04
Authors: Kelly R Reveles; Kenneth A Lawson; Eric M Mortensen; Mary Jo V Pugh; Jim M Koeller; Jacqueline R Argamany; Christopher R Frei Journal: PLoS One Date: 2017-12-07 Impact factor: 3.240